## FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

December 1, 2003

OFFICIAL

TO:

Examiner Ruixiang Li

Group 1646 (703) 306-0282

RECEIVED
CENTRAL FAX CENTER

FROM

Justin D. Karjala

Celera Genomics Corp.

(240) 453-3812

DEC 0 1 2003

FAX NO:	(703)872-9306		
# OF PAGES (incl. cover):	6		

Re: U.S. Serial No. 09/900,448, filed July 9, 2001

Entitled "ISOLATED HUMAN SECRETED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED PROTEINS, AND USES

THEREOF"

Atty. Docket No.: CL001272

A Preliminary Amendment (Restriction Election) and a Petition for a One-Month Extension of Time in the above-identified application follows.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

PTO/SB/22 (10-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person	are required to rospon	d to a collection of information ur	desa if displays a valid OMB control number		
PETITION FOR EXTENSION OF	TIME UNDER	37 CFR 1.136(a)	Docket Number (Optional) CL001272		
	In re Application of	Toni CECCARE	OI et al.		
	Application Number	09/900,448	Filed July 9, 2001		
For ISOLATED HUMAN SECRETED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED					
	Group Art Unit	1646	Examiner R. Li		
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filling a reply in the above identified application.					
The requested extension and appropriate non-small-entity fee are as follows (check time period desired):					
☑ One month (37 CFR 1.17(a)(1))		\$110 Fee Code 115 s 110.00			
Two months (27 CER 1 17/s	11/211	\$410 Fee Co	\$410 Fee Code 116		
Two months (37 CFR 1.17(a)(2))		4000 E 0 1 110			
Three months (37 CFR 1.17(a)(3))		\$1450 Fee Co	• • • • • • • • • • • • • • • • • • •		
Four months (37 CFR 1.17(a)(4))		\$1450 Fee Code 118 \$ \$1970 Fee Code 128 &			
Five months (37 CFR 1.17(a	\$1970 Pee CC	\$			
Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$  A check in the amount of the fee is enclosed.  Payment by credit card. Form PTO-2038 is attached.  The Commissioner has already been authorized to charge fees in this application to a Deposit Account.  The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number					
I have enclosed a duplicate copy of	of this sheet.				
I am the applicant/inventor					
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).					
attorney or agent of record.					
attorney or agent under 37 CFR 1.34(a).  Registration number if acting under 37 CFR 1.34(a)					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
December 1, 2003		C/101			
Date		Signa	iture		
	•	Justin D. Karja	la, Reg. No. 43,704		
		Typed	or printed name		
NOTE: Signatures of all the inventors of sasignass of record of the antire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.					
☐ Total offorms are submitted					

Surden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.